ITCI Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:

Evercore 7th Annual HealthCONx Conference

Tuesday, December 3, 2024 at 10:50 a.m. ET in Miami, FL

Citi 2024 Global Healthcare Conference

Wednesday, December 4, 2024 at 3:15 p.m. ET in Miami, FL

Piper Sandler 36th Annual Healthcare Conference

Thursday, December 5, 2024 at 11:30 a.m. ET in New York, NY

A live and achieved webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the Company's website at Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit .

Contact:

Intra-Cellular Therapies, Inc.

Juan Sanchez, M.D.

Vice President, Corporate Communications and Investor Relations

646-440-9333

Burns McClellan, Inc.

Cameron Radinovic



646-930-4406



EN
19/11/2024

Underlying

ITCIIntra-Cellular Therapies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intra-Cellular Therapies Inc.

 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies to Participate in Three Upcoming Investor Con...

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences: Evercore 7th Annual HealthCONx ConferenceTuesday, December 3, 2024 at 10:50 a.m. ET in Miami, FL Citi 2024 Global Healthcare Conferenc...

November 19, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Con...

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Results show robust efficacy and favorable safety and tolerability profile for CAPLYTA BEDMINSTER, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...

November 7, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3...

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was demonstrated in a randomized withdrawal trial The study demonstrated a statistically significant (p=0.0002) longer time to relapse in schizophrenia patients treated with lumateperone compared to placebo BEDMINSTER, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical com...

November 5, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results,...

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA’s strong prescription uptake continues: Q3 2024 CAPLYTA total prescriptions increased 38%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance range raised to $665 to $685 million Following a successful pre-supplemental NDA (sNDA) meeting with the U.S. Food and Drug Administrati...

October 30, 2024 1 EN
 PRESS RELEASE
Free
ITCI Intra-Cellular ...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results ...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, October 30, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2024. To atten...

October 17, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch